3 days Ago By ABMN Staff
Analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals ( NASDAQ:TTNP – Get Free Report ) in a research note issued on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Up 0.2 % TTNP stock opened at $5.54 on Friday.
Titan Pharmaceuticals has a 1 year low of $4.24 and a 1 year high of $14.80.
The company has a 50 day simple moving average of $5.84 and a 200 day simple moving average of $6.51.
Titan Pharmaceuticals ( NASDAQ:TTNP – Get Free Report ) last released its earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
About Titan Pharmaceuticals Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
